

August 13, 2026

To, National Stock Exchange of India Limited, "Exchange Plaza", 5th Floor, Plot No. C/1, G Block, Bandra- Kurla Complex, Bandra (East), Mumbai – 400 051	To, BSE Limited, Corporate Relationship Department, 2nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai – 400 001
Scrip Name: GLENMARK	Scrip Code: 532296
ISIN: INE935A01035	ISIN: INE935A01035
Our Reference No. 49/26-27	Our Reference No. 49/26-27

Dear Sir/ Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulations 30 and 36(1)(b) of the SEBI Listing Regulations, we wish to inform that the letters are being sent by the Company to those Shareholders whose e-mail addresses are not registered with the Company/ Registrar & Transfer Agent/ Depository Participants, providing the web-link and QR Code of Company's website from where the Integrated Annual Report and Annual General Meeting Notice for FY 2025-26 can be accessed.

A copy of the letter is enclosed herewith for your record and the same is also uploaded on the website of the Company at www.glenmarkpharma.com

You are requested to take the above information on record.

Thanking You

Yours Faithfully,

For Glenmark Pharmaceuticals Limited

Rashmi Khandelwal
Company Secretary & Compliance Officer
ACS – 28839
Encl: As above

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com



Glenmark Pharmaceuticals Limited

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road,
Mumbai – 400 026; Corporate Office: Glenmark House, B. D. Sawant Marg,
Chakala, Off. Western Express Highway, Andheri (E), Mumbai – 400099.

Phone No: +91 22 4018 9999; Fax No.: +91 22 4018 9986;

CIN: L24299MH1977PLC019982;

Website: www.glenmarkpharma.com; Email:
complianceofficer@glenmarkpharma.com

NOTICE OF THE 48TH ANNUAL GENERAL MEETING ALONG WITH THE INTEGRATED ANNUAL REPORT

Dear Members,

We are pleased to inform you that the 48th Annual General Meeting (“AGM”) of Glenmark Pharmaceuticals Limited (“the Company”) is scheduled to be held on Friday, September 11, 2026 at 2.00 P.M. (IST) through Video Conference (“VC”) / Other Audio-Visual Means (“OAVM”), in compliance with the various circulars issued by Ministry of Corporate Affairs (“MCA”) and Securities and Exchange Board of India (“SEBI”) from time to time.

The Notice of the 48th AGM along with the Integrated Annual Report for the Financial Year 2025-26 is being sent by electronic mode to Members whose e-mail ids are registered with the Company/ Registrar & Share Transfer Agent (“RTA”) or the Depository Participants (“DPs”). In terms of Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, in the absence of your email id registered with the RTA/ Depository Participant, this letter is being sent to you to provide the web-link and QR Code along with the path to access the Annual Report and Notice of AGM of Company, which is given below:

Particulars	Web-Link	QR Code	Website Path
Notice of AGM	https://glenmark.b-cdn.net/gpl_pdfs/investors/reports_presentations/AGM%20NOTICE.pdf		https://glenmarkpharma.com/annual-report/ → FY 2025-26 → AGM Notice 2025-26 (Download)
Integrated Report for Financial Year 2025-26	https://glenmark.b-cdn.net/gpl_pdfs/investors/reports_presentations/Annual%20Report%202025-26%20%28Low%20Version%29.pdf		https://glenmarkpharma.com/annual-report/ → FY 2025-26 → Annual Report 2025-26 (Download)

Members can opt for permanent registration of their e-mail address with their concerned DPs, in respect of shares held in dematerialized form and with RTA in respect of shares held in physical form, by writing to einward.ris@kfintech.com / Complianceofficer@glenmarkpharma.com.

We sincerely appreciate your continued support and look forward to your cooperation in embracing our journey towards greater digitization and seamless communication.

For Glenmark Pharmaceuticals Limited

Sd/-

Rashmi Khandelwal

Company Secretary & Compliance Officer

Date: August 13, 2026

Place: Mumbai